Overall survival. (A) Overall survival according to randomization. One hundred seventy-five patients assigned to fludarabine and 176 patients assigned to FC were evaluable for overall survival. Seventeen patients treated with fludarabine and 20 patients treated with FC died (P = .74). Median overall survival has not been reached in either arm. (B) Overall survival according to randomization and response. One hundred sixty-four patients assigned to fludarabine and 164 patients assigned to FC were evaluable for overall survival and response. Of the 28 patients without response to fludarabine therapy (stable disease or progressive disease), 3 have died. In the FC group, 9 patients had no response, and 5 of these patients died (P = .006). Median overall survival in the FC nonresponder group was 30 months; in the fludarabine arm, median overall survival has not yet been reached.